Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetics and Pharmacodynamics of LY2963016 Compared to Lantus in Healthy Subjects Following Two Single Subcutaneous Doses

Next Previous
Trial Profile

Pharmacokinetics and Pharmacodynamics of LY2963016 Compared to Lantus in Healthy Subjects Following Two Single Subcutaneous Doses

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 13 Jun 2014 Primary endpoint of maximum Serum LY2963016 or Lantus Concentration (Cmax) has not been met according to results presented at the 74th Annual Scientific Sessions of the American Diabetes Association.
    • 13 Jun 2014 Primary endpoint of Area Under the Serum LY2963016 or Lantus Concentration-Time Curve (AUC) From Zero to Infinity [AUC(0-) has been met, according to results presented at the 74th Annual Scientific Sessions of the American Diabetes Association.
    • 28 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top